## Lepra Reaction Type 2 (Erythema Nodosum Leprosum) ### Clinical Recognition **Key Point:** This patient has ENL (Erythema Nodosum Leprosum), a Type III hypersensitivity reaction (immune complex-mediated) occurring in lepromatous and borderline lepromatous leprosy patients, typically 6 months to 2 years after starting MDT. **Clinical Pearl:** The triad of fever, painful nodules (often on extensor surfaces), and neuritis with neutrophilic infiltration and immune complex deposition on histology is pathognomonic for ENL. ### Management Algorithm ```mermaid flowchart TD A[ENL diagnosed]:::outcome --> B{Severity assessment}:::decision B -->|Mild: few lesions, no neuritis| C[Continue MDT + NSAIDs/Aspirin]:::action B -->|Moderate: multiple lesions, mild neuritis| D[Continue MDT + Prednisolone 0.5-1 mg/kg/day]:::action B -->|Severe: extensive lesions, severe neuritis/iritis| E[Continue MDT + Prednisolone 1-2 mg/kg/day ± Thalidomide]:::action C --> F[Monitor clinical response]:::action D --> F E --> F F --> G[Taper steroids over 12-24 weeks]:::action ``` ### Rationale for Correct Answer **High-Yield:** The cardinal rule in ENL management is **CONTINUE MDT while treating the reaction**. Stopping MDT allows bacillary multiplication and worsening of leprosy itself. 1. **Systemic corticosteroids** are the first-line anti-inflammatory agent for moderate-to-severe ENL (this patient has neuritis, placing him in the moderate-severe category). 2. Prednisolone at 0.5–1 mg/kg/day is the standard starting dose; higher doses (1–2 mg/kg/day) are reserved for severe cases with ocular or neurological involvement. 3. Gradual taper over 12–24 weeks prevents rebound reaction. **Key Point:** NSAIDs (aspirin, ibuprofen) are adequate for mild ENL; corticosteroids are mandatory once neuritis or systemic features are present. ### Role of Thalidomide - Reserved for **steroid-dependent or steroid-resistant** ENL (after 2–4 weeks of prednisolone without improvement). - Not first-line; not indicated at presentation. ### Why MDT Continues ENL is a host immune response to dead bacilli, not active infection. Stopping MDT: - Allows viable bacilli to proliferate. - Converts the patient back to a higher bacillary load state. - Worsens long-term prognosis. [cite:Park 26e Ch 6] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.